ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

Konwar S, Schroda S, Rogg M, et al. Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Invest.

The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to a press release from ...

The US Food and Drug Administration (FDA) recently granted fast track designation to Sanofi’s SAR446597 for the treatment of geographic atrophy (GA). 1 ...

Paris: Sanofi has received fast track designation from the US Food and Drug Administration (FDA) for SAR446597, a one-time ...

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a clinical ...

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit ...

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related ...

US FDA grants fast track designation to Sanofi’s SAR446597 to treat geographic atrophy due to age-related macular degeneration: Paris Thursday, July 17, 2025, 10:00 Hrs [IST] Th ...

SEOUL, South Korea — ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its ...

In addition to autoantibody-mediated activation of the classical complement pathway, MG pathogenesis is also significantly influenced by activation of the alternative pathway.